19 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients (MERCURIC)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2020,
Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omi ...
Voir le projet
13
Participants partenaires
TERMINÉ
iABC Programme (IABC PROGRAMME)
Date du début: 1 août 2015, Date de fin: 31 juil. 2020,
Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomon ...
Voir le projet
21
Participants partenaires
TERMINÉ
Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,
Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet
44
Participants partenaires
TERMINÉ
Combatting Bacterial Resistance in Europe - Carbapenem Resistance (COMBACTE-CARE)
Date du début: 1 mars 2015, Date de fin: 28 févr. 2020,
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (M ...
Voir le projet
23
Participants partenaires
TERMINÉ
DC-based immunotherapy to treat Malignant Mesothelioma (H2020MM04)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millio ...
Voir le projet
8
Participants partenaires
TERMINÉ
Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS (ARREST BLINDNESS)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medic ...
Voir le projet
14
Participants partenaires
TERMINÉ
Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies (DISCHARGE)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
Coronary artery disease (CAD) is the leading cause of death in high-income countries. Invasive coronary angiography (ICA) is the reference standard for the diagnosis of CAD and allows immediate therapy. However, only 40% of patients undergoing ICA actually have obstructive CAD and ICA has relatively rare but considerable risks. Coronary computed tomography (CT) is the most accurate diagnostic test ...
Voir le projet
38
Participants partenaires
TERMINÉ
Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis (Myasterix)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
The MYASTERIX project will advance a therapeutic vaccine candidate (designated orphan drug) indicated for the autoimmune disease myasthenia gravis (MG) to clinical proof of concept studies. MG is caused by T cell dependent antibodies that bind to and deplete acetylcholine receptors (AChR) at neuromuscular junctions causing muscle weakness by interfering with neuromuscular transmission and junction ...
Voir le projet
6
Participants partenaires
TERMINÉ
Scalda Europese Mobiliteit 2016 - 2018
Date du début: 1 sept. 2016, Date de fin: 31 août 2018,
The policy of Scalda concerning International learning is aimed on integration of international learning in the curriculum of the VET education. Each cluster of education is responsible for the just how fast this process will be and to what extent.Scalda has written in 2013 a policy on international learning and each cluster of education will scan the position of the cluster on international lear ...
Voir le projet
17
Participants partenaires
TERMINÉ
Cancer Vaccine development for Hepatocellular Carcinoma (HepaVac)
Date du début: 1 sept. 2013, Date de fin: 31 août 2018,
"Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. Given the lack of available effective treatments, the overall prognosis for HCC patients is poor, with a dismal 5-year survival of 5-6%. The main goal of this proposal is to develop a therapeutic cancer vaccine aiming at improving clinical outcome in early-stage HCC ...
Voir le projet
10
Participants partenaires
TERMINÉ
QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)
Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet
26
Participants partenaires
TERMINÉ
A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol (RESOLVE)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
"Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the disturbed dynamics and mechanisms underlying the high triglyceride (HTG) and low high-density lipoprotein cholesterol (HDL-C) phenotype and insulin resistance in patients with metabolic syndrome (MetS) and its associated co-morbidities (cardiovascular disease, CV ...
Voir le projet
14
Participants partenaires
TERMINÉ
Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn (THE HIP TRIAL)
Date du début: 1 oct. 2010, Date de fin: 30 sept. 2017,
Assuming an annual birth rate of 10.25 births/1,000 population approximately 25,000 Extremely Low Gestational Age Newborns are born every year in the EU. Conservative figures estimate that approximately half of all these babies will develop low blood pressure and require treatment. However, no uniform criteria exist to define hypotension and the evidence to support our current management strategie ...
Voir le projet
17
Participants partenaires
TERMINÉ
Multivessel versus culprit lesion only percutaneous revascularization in patients with acute myocardial infarction complicated by cardiogenic shock (CULPRIT-SHOCK)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) represents a major European health care concern with mortality rates between 40-70%. Approximately 70-80% of these patients present with multivessel disease defined as coronary lesions in more than one vessel. The clinician is faced with the decision to either 1) intervene only on the culprit lesion acutely responsible for the i ...
Voir le projet
23
Participants partenaires
TERMINÉ
Scalda Europese Mobiliteit 2015-2017
Date du début: 1 juin 2015, Date de fin: 31 mai 2017,
The policy of Scalda concerning International learning is aimed on integration of international learning in the curriculum of the VET education. Each cluster of education is responsible for the just how fast this process will be and to what extent.
Scalda has written in 2013 a policy on international learning and each cluster of education will scan the position of the cluster on international lea ...
Voir le projet
15
Participants partenaires
TERMINÉ
Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure (OptimEx)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2017,
More than 14 million Europeans suffer from heart failure (HF), of which more than 50 % have HF with preserved left ventricular (LV) ejection fraction (EF) (HFPEF, “diastolic heart failure”). HFPEF is the only cardiovascular disease with increasing prevalence and incidence, affecting 10-20% of the elderly and contributing substantially to hospitalizations of elderly HF patients. Currently, no medic ...
Voir le projet
9
Participants partenaires
TERMINÉ
Bioactive Implantable Polymers based on UreidoPyrimidinone (BIP-UPy)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2017,
BIP-UPy addresses the need for biomedical implants which can be easily fine-tuned in their properties in regards to bioactivity, biodegradability, and mechanical performance, and thereby be optimized for their targeted clinical application.This project will develop a library comprising of a selection of synthetic polymers and specific bioactivities which can be used to provide the required propert ...
Voir le projet
11
Participants partenaires
TERMINÉ
Training Urology Scientists to develop Treatments (TRUST)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,
"Urinary Incontinence (UI) affects around 10% of the population (more than 70 Million people in the EU) and unfortunately - due to the aging population - is an increasing cause of impaired quality of life. The most common cause of UI is called the Overactive bladder syndrome (OABS) of which the underlying complex bio-molecular mechanisms are poorly understood. Many distinct tissues (nervous system ...
Voir le projet
11
Participants partenaires
TERMINÉ
Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria (SATURN)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,
"Many results drawn from previous studies of the effect of antibiotic use on emergence, selection and spread of antimicrobial resistance (AMR) have lacked a holistic view combining all aspects into one study. The SATURN project aims to study the impact of antibiotic exposure on AMR with a multidisciplinary approach that bridges molecular, epidemiological, clinical and pharmacological research. Two ...
Voir le projet